Caroline Jamison Debra Nelson Mete Eren Dron Gauchan Ryan Ramaekers Max Norvell Mehmet Sitki Copur
10.3727/096504015X14452563485986
Oncol Res
2016 Jan 21;23(1-2):1-5.
CC BY-NC-ND
https://pubmed.ncbi.nlm.nih.gov/26802644/
Antineoplastic Agents / administration & dosage Dasatinib / administration & dosage Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Antineoplastic Agents / administration & dosage Dasatinib / administration & dosage Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis Case Reports Review Adult Drug Administration Schedule Female Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Male Middle Aged Treatment Outcome Antineoplastic Agents Dasatinib
PMC7842568
26802644
What Is the Optimal Dose and Schedule for Dasatinib in Chronic Myeloid Leukemia: Two Case Reports and Review of the Literature
2016